Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05312710Phase 2Active Not Recruiting

Safety and Efficacy of APG-157 in Head and Neck Cancer

Role: lead

NCT05865028Phase 2Recruiting

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

Role: collaborator

NCT06011109Phase 1Recruiting

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

Role: lead

NCT05551013Unknown

Treatment of Recurrent GBM With APG-157 Via Expanded Access

Role: lead

All 4 trials loaded